Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Increased reactive oxygen species production and p47phox phosphorylation in neutrophils from myeloproliferative disorders patients with JAK2 (V617F) mutation.

Hurtado-Nedelec M, Csillag-Grange MJ, Boussetta T, Belambri SA, Fay M, Cassinat B, Gougerot-Pocidalo MA, Dang PM, El-Benna J.

Haematologica. 2013 Oct;98(10):1517-24. doi: 10.3324/haematol.2012.082560. Epub 2013 Aug 23.

2.

A specific p47phox -serine phosphorylated by convergent MAPKs mediates neutrophil NADPH oxidase priming at inflammatory sites.

Dang PM, Stensballe A, Boussetta T, Raad H, Dewas C, Kroviarski Y, Hayem G, Jensen ON, Gougerot-Pocidalo MA, El-Benna J.

J Clin Invest. 2006 Jul;116(7):2033-43. Epub 2006 Jun 15.

3.

Zymosan induces NADPH oxidase activation in human neutrophils by inducing the phosphorylation of p47phox and the activation of Rac2: involvement of protein tyrosine kinases, PI3Kinase, PKC, ERK1/2 and p38MAPkinase.

Makni-Maalej K, Chiandotto M, Hurtado-Nedelec M, Bedouhene S, Gougerot-Pocidalo MA, Dang PM, El-Benna J.

Biochem Pharmacol. 2013 Jan 1;85(1):92-100. doi: 10.1016/j.bcp.2012.10.010. Epub 2012 Oct 22.

PMID:
23085266
4.

The TLR7/8 agonist CL097 primes N-formyl-methionyl-leucyl-phenylalanine-stimulated NADPH oxidase activation in human neutrophils: critical role of p47phox phosphorylation and the proline isomerase Pin1.

Makni-Maalej K, Boussetta T, Hurtado-Nedelec M, Belambri SA, Gougerot-Pocidalo MA, El-Benna J.

J Immunol. 2012 Nov 1;189(9):4657-65. doi: 10.4049/jimmunol.1201007. Epub 2012 Sep 21.

5.

A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression.

Marty C, Lacout C, Droin N, Le Couédic JP, Ribrag V, Solary E, Vainchenker W, Villeval JL, Plo I.

Leukemia. 2013 Nov;27(11):2187-95. doi: 10.1038/leu.2013.102. Epub 2013 Apr 5.

PMID:
23558526
6.

JAK2 V617F uses distinct signalling pathways to induce cell proliferation and neutrophil activation.

Oku S, Takenaka K, Kuriyama T, Shide K, Kumano T, Kikushige Y, Urata S, Yamauchi T, Iwamoto C, Shimoda HK, Miyamoto T, Nagafuji K, Kishimoto J, Shimoda K, Akashi K.

Br J Haematol. 2010 Aug;150(3):334-44. doi: 10.1111/j.1365-2141.2010.08249.x. Epub 2010 Jun 10.

PMID:
20553273
7.

JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders.

Rumi E, Passamonti F, Pietra D, Della Porta MG, Arcaini L, Boggi S, Elena C, Boveri E, Pascutto C, Lazzarino M, Cazzola M.

Cancer. 2006 Nov 1;107(9):2206-11.

8.

Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression.

Moliterno AR, Williams DM, Rogers O, Spivak JL.

Blood. 2006 Dec 1;108(12):3913-5. Epub 2006 Aug 15.

9.

The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms.

Borowczyk M, Wojtaszewska M, Lewandowski K, Gil L, Lewandowska M, Lehmann-Kopydłowska A, Kroll-Balcerzak R, Balcerzak A, Iwoła M, Michalak M, Komarnicki M.

Thromb Res. 2015 Feb;135(2):272-80. doi: 10.1016/j.thromres.2014.11.006. Epub 2014 Nov 15.

PMID:
25559461
10.

JAK2-V617F mutation in Moroccan patients with myeloproliferative disorders: contribution, diagnosis and therapeutic prospects.

Benmoussa A, Dehbi H, Fehri S, Quessar A, Nadifi S.

Pathol Biol (Paris). 2011 Aug;59(4):e89-92. doi: 10.1016/j.patbio.2009.06.005. Epub 2009 Nov 24.

PMID:
19939582
11.
12.

Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellular transformation.

Kamishimoto J, Tago K, Kasahara T, Funakoshi-Tago M.

Cell Signal. 2011 May;23(5):849-56. doi: 10.1016/j.cellsig.2011.01.009. Epub 2011 Jan 19.

PMID:
21255641
13.

Anti-inflammatory effect of interleukin-10 on human neutrophil respiratory burst involves inhibition of GM-CSF-induced p47PHOX phosphorylation through a decrease in ERK1/2 activity.

Dang PM, Elbim C, Marie JC, Chiandotto M, Gougerot-Pocidalo MA, El-Benna J.

FASEB J. 2006 Jul;20(9):1504-6. Epub 2006 May 23.

PMID:
16720733
14.

JAK2 (V617F) mutation is not associated with thrombosis in Behcet syndrome.

Ar MC, Hatemi G, Ekizoğlu S, Bilgen H, Saçli S, Buyru AN, Soysal T, Ülkü B, Yazici H.

Clin Appl Thromb Hemost. 2012 Jul;18(4):421-6. doi: 10.1177/1076029611427440. Epub 2011 Dec 26.

PMID:
22203033
15.

Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation.

Bang SM, Lee JS, Ahn JY, Lee JH, Hyun MS, Kim BS, Park MR, Chi HS, Kim HY, Kim HJ, Lee MH, Kim H, Won JH, Yoon HJ, Oh DY, Nam EM, Bae SH, Kim BK; Korean MPN Working Party.

Thromb Haemost. 2009 Mar;101(3):547-51.

PMID:
19277418
16.

TLR8, but not TLR7, induces the priming of the NADPH oxidase activation in human neutrophils.

Makni-Maalej K, Marzaioli V, Boussetta T, Belambri SA, Gougerot-Pocidalo MA, Hurtado-Nedelec M, Dang PM, El-Benna J.

J Leukoc Biol. 2015 Jun;97(6):1081-7. doi: 10.1189/jlb.2A1214-623R. Epub 2015 Apr 15.

17.

Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms.

Takata Y, Seki R, Kanajii T, Nohara M, Koteda S, Kawaguchi K, Nomura K, Nakamura T, Morishige S, Oku E, Osaki K, Hashiguchi E, Mouri F, Yoshimoto K, Nagafuji K, Okamura T.

Kurume Med J. 2014;60(3-4):89-97. Epub 2014 May 26.

18.

Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens.

Moliterno AR, Williams DM, Rogers O, Isaacs MA, Spivak JL.

Exp Hematol. 2008 Nov;36(11):1480-6. doi: 10.1016/j.exphem.2008.05.006. Epub 2008 Aug 23.

19.

The prolyl isomerase Pin1 acts as a novel molecular switch for TNF-alpha-induced priming of the NADPH oxidase in human neutrophils.

Boussetta T, Gougerot-Pocidalo MA, Hayem G, Ciappelloni S, Raad H, Arabi Derkawi R, Bournier O, Kroviarski Y, Zhou XZ, Malter JS, Lu PK, Bartegi A, Dang PM, El-Benna J.

Blood. 2010 Dec 23;116(26):5795-802. doi: 10.1182/blood-2010-03-273094. Epub 2010 Oct 18.

20.

JAK2 V617F mutation status of 232 patients diagnosed with chronic myeloproliferative neoplasms.

Payzin KB, Savasoglu K, Alacacioglu I, Ozdemirkiran F, Mutlu BB, Bener S, Calli AO, Kucukzeybek BB, Aksun S.

Clin Lymphoma Myeloma Leuk. 2014 Dec;14(6):525-33. doi: 10.1016/j.clml.2014.02.013. Epub 2014 Mar 5.

PMID:
24811089

Supplemental Content

Support Center